We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 16, 2020

Nanoparticle Polymeric Micellar Paclitaxel vs Solvent-Based Paclitaxel as First-Line Treatment of Advanced NSCLC

Annals of Oncology


Additional Info

Annals of Oncology
Comparing Nanoparticle Polymeric Micellar Paclitaxel and Solvent-Based Paclitaxel as First-Line Treatment of Advanced Non-Small Cell Lung Cancer: An Open-Label, Randomized, Multicenter, Phase III Trial
Ann. Oncol 2020 Oct 28;[EPub Ahead of Print], M Shi, A Gu, H Tu, et al

Further Reading